PTO/SB/08B (04-07)

Approved for use through 09/30/2007, OMB 0651-0031

421-US-PCT

Substitute for form 1449/PTO	required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
	Application Number	10/540,075		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	June 22, 2005 Mario Rottlander		
	First Named Inventor			
(Use as many sheets as necessary)	Art Unit	1626		
	Examiner Name	Deborah C. Lambido Reitsang Shia		

Attorney Docket Number

Sheet

1

1

of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		
nitials*			T ²	
/R.S./		WICKENDEN, et al. "Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels" Molecular Pharmacology, 2000, 58, 591-600		
		TOBER, et al. "D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures" European Journal of Pharmacology, 1996, 303, 163-169		
		WICKENDEN, et al. "KCNQ Channel Expression in Rat DRG Following Nerve Ligation" Society for Neuroscience Abstracts, 2002, No. 454.7		
		GOLDSTEIN, et al. "Localization of KCNQ and KCNE Channel Subunits in the Central and Peripheral Nervous System of the Rat" Society for Neuroscience Abstracts, 2003, No. 53.8		
		SAGANICH, et al. "Differential Expression of Genes Encoding Subthreshold-Operating Voltage-Gated K+ Channels in Brain" The Journal of Neuroscience, 2001, 21, 4609-4624		
/R.S./ NOD 2003		NODA, et al. "KCN Channels in Glial Cells" Society for Neuroscience Abstracts, 2003, No. 53.9		
		·		
		·	******	

Examiner	/Doi Toong China/	Data	
	/Rei Tsang Shiao/	Date	l
Signature	5		09/05/2007
Oignature		Considered	03/03/2001
	·		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: